Insulet Management

Management criteria checks 3/4

Insulet's CEO is Jim Hollingshead, appointed in Jun 2022, has a tenure of 2.42 years. total yearly compensation is $12.38M, comprised of 6.8% salary and 93.2% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth MX$92.71M. The average tenure of the management team and the board of directors is 2.4 years and 4 years respectively.

Key information

Jim Hollingshead

Chief executive officer

US$12.4m

Total compensation

CEO salary percentage	6.8%
CEO tenure	2.4yrs
CEO ownership	0.02%
Management average tenure	2.4yrs
Board average tenure	4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jim Hollingshead's remuneration changed compared to Insulet's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	US$421m
Jun 30 2024	n/a	n/a	US$395m
Mar 31 2024	n/a	n/a	US$234m
Dec 31 2023	US$12m	US$842k	US$206m
Sep 30 2023	n/a	n/a	US$120m
Jun 30 2023	n/a	n/a	US$63m
Mar 31 2023	n/a	n/a	US$600k
Dec 31 2022	US$11m	US$440k	US$5m
Sep 30 2022	n/a	n/a	US$17m
Jun 30 2022	n/a	n/a	US$35m
Mar 31 2022	n/a	n/a	US$45m
Dec 31 2021	US$290k	n/a	US$17m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	US$9m
Dec 31 2020	US$259k	n/a	US$7m
Sep 30 2020	n/a	n/a	US$29m
Jun 30 2020	n/a	n/a	US$18m
Mar 31 2020	n/a	n/a	US$5m
Dec 31 2019	US$261k	n/a	US$12m

Compensation vs Market: Jim's total compensation ($USD12.38M) is above average for companies of similar size in the MX market ($USD5.74M).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.

CEO

Jim Hollingshead (61 yo)

2.4yrs

Tenure

US$12,379,765

Compensation

Dr. James R. Hollingshead, also known as Jim, Ph.D. had been President of Sleep & Respiratory Care Business at ResMed Inc. since July 2020 until May 05, 2022 and served as its President of Sleep Business s...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Hollingshead	President	2.4yrs	US$12.38m	0.025% MX$ 92.7m
Lauren Budden	Group VP	5.6yrs	US$1.44m	0.0061% MX$ 22.8m
Mark Field	Senior VP & CTO	1.3yrs	US$2.37m	0.014% MX$ 51.8m
John Kapples	Senior VP & General Counsel	5.7yrs	US$2.47m	0.021% MX$ 79.7m
Eric Benjamin	Executive VP	6.8yrs	US$3.14m	0.024% MX$ 89.5m
Ana Chadwick	Executive VP	less than a year	no data	0.00014% MX$ 520.8k
Prem Singh	Senior Vice President of Global Operations	1.8yrs	no data	0.0052% MX$ 19.4m
Deborah Gordon	Vice President of Investor Relations	9.8yrs	no data	no data
Laetitia Cousin	Senior VP of Regulatory Affairs	1.9yrs	no data	0.0044% MX$ 16.5m
Angela Wiczek	Senior Director of Corporate Communications	no data	no data	no data
Philip Hildale	Senior Vice President of Sales & Customer Care	9.8yrs	no data	no data
Andrew Isaacson	Senior VP of Strategy & Corporate Development	less than a year	no data	no data

2.4yrs

Average Tenure

52yo

Average Age

Experienced Management: PODD *'s management team is considered experienced (2.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
James Hollingshead	President	5.3yrs	US$12.38m	0.025% MX$ 92.7m
Elizabeth Weatherman	Independent Director	2.8yrs	US$322.50k	0.0040% MX$ 14.7m
Timothy Scannell	Independent Chairman	10.3yrs	US$387.10k	0.042% MX$ 154.9m
Robert Sherwin	Chairman of Scientific Advisory Board	no data	no data	no data
Howard Wolpert	Member of Scientific Advisory Board	no data	no data	no data
Margaret Lawlor	Member of Educator Advisory Board	no data	no data	no data
Camille Izlar	Member of Educator Advisory Board	no data	no data	no data
Mary Halvorson	Member of Educator Advisory Board	no data	no data	no data
Steven Edelman	Member of Scientific Advisory Board	no data	no data	no data
Anne Daly	Member of Educator Advisory Board	no data	no data	no data
John Buse	Member of Scientific Advisory Board	no data	no data	no data
Timothy Stonesifer	Independent Director	less than a year	no data	no data

4.0yrs

Average Tenure

61yo

Average Age

Experienced Board: PODD *'s board of directors are considered experienced (4 years average tenure).

Insulet Management

Management criteria checks 3/4

Key information

Recent management updates

Insider recently sold Mex$2.9m worth of stock

Senior VP & CTO recently sold Mex$6.1m worth of stock

Senior VP & CTO recently sold Mex$5.5m worth of stock

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Announces Board Changes

Recent updates

Insider recently sold Mex$2.9m worth of stock

Investor sentiment improves as stock rises 17%

Third quarter 2024 earnings released: EPS: US$1.11 (vs US$0.74 in 3Q 2023)

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Omnipod 5 App for Iphone Now Fully Available in the United States

Insulet Corporation to Report Q3, 2024 Results on Nov 07, 2024

Senior VP & CTO recently sold Mex$6.1m worth of stock

Investor sentiment improves as stock rises 19%

Senior VP & CTO recently sold Mex$5.5m worth of stock

Insulet Corporation Announces Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Insulet Corporation to Report Q2, 2024 Results on Aug 08, 2024

Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation to Report Q1, 2024 Results on May 09, 2024

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial (RCT) Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)

Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes

Full year 2023 earnings released: EPS: US$2.96 (vs US$0.066 in FY 2022)

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Insulet Corporation Announces Board Changes

Insulet Corporation to Report Q4, 2023 Results on Feb 22, 2024

Director & Advisor recently sold Mex$43m worth of stock

Third quarter 2023 earnings released: EPS: US$0.74 (vs US$0.075 loss in 3Q 2022)

Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Year Ending December 31, 2023

Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone

Insulet Corporation Announces CFO Transition

Insulet Corporation to Report Q3, 2023 Results on Nov 02, 2023

Insulet Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System in Germany

Second quarter 2023 earnings released: EPS: US$0.39 (vs US$0.51 loss in 2Q 2022)

Executive VP recently sold Mex$6.7m worth of stock

Insulet Corporation to Report Q2, 2023 Results on Aug 08, 2023

Insulet Corporation Announces Omnipod 5 Automated Insulin Delivery System Is Now Available in the United Kingdom

Insider recently sold Mex$2.5m worth of stock

Insider recently bought Mex$18m worth of stock

Bret Christensen, Executive Vice President, Chief Commercial Officer Will Be Leaving Insulet Corporation

Insulet Corporation (NasdaqGS:PODD) acquired Assets of Automated Glucose Control LLC for $25 million.

Insulet Corporation to Report Q4, 2022 Results on Feb 23, 2023

Insulet Corporation Announces Executive Changes

Executive VP & Chief Commercial Officer recently sold Mex$17m worth of stock

Insulet Corporation Announces Medical Device Correction for the Omnipod 5 Automated Insulin Delivery System

Insulet Corporation Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022

Insulet Corporation Provides Revenue Guidance for the Quarter Ending December 31, 2022

Insulet Corporation to Report Q3, 2022 Results on Nov 03, 2022

Insulet Corporation Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes

Insulet Corporation Provides Revenue Guidance for the Quarter Ending September 30, 2022 and Year Ending December 31, 2022

Insulet Corporation Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System

Insulet Corporation to Report Q2, 2022 Results on Aug 04, 2022

Executive VP & COO recently sold Mex$25m worth of stock

Omnipod(R) 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

Dexcom Says Not in Active Merger Talks

Dexcom Reportedly in Talks to Acquire Insulet

Insulet Corporation Provides Revenue Guidance for the Quarter Ending June 30, 2022 and Full Year Ending December 31, 2022

Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes

Insulet Corporation, Annual General Meeting, May 24, 2022

Insulet Corporation to Report Q1, 2022 Results on May 05, 2022

Insulet Corporation Provides Revenue Guidance for the First Quarter Ending March 31, 2022 and Year Ending December 31, 2022

Insulet Corporation Promotes Inclusivity for People with Diabetes Through Nintendo® Video Game Animal Crossing™: New Horizons

Insulet Corporation Announces Board Changes

Insulet Corporation Announces FDA Clearance of Its Omnipod 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members